期刊
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY
卷 18, 期 4, 页码 717-733出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2004.04.003
关键词
dyspepsia; functional; gastric accommodation; visceral sensitivity; proton pump inhibitors; prokinetics; Helicobacter pylori; scrotonergic agents; CCK antagonist; opioid antagonist
The therapeutic management of functional dyspepsia remains a major challenge for the gastroenterologist. Current therapies available are based on putative underlying pathophysiologic mechanisms, including gastric acid sensitivity, slow gastric emptying and Helicobacter pylori infection, but only a small proportion of patients achieve symptomatic benefit from these therapeutic approaches. Relatively novel mechanistic concepts under testing include impaired gastric accomoclation, visceral hypersensitivity, and central nervous system dysfunction. Serotonergic modulators (e.g. the 5-HT4 agonist tegaserod, the 5-HT3 antagonist alosetron and the 5-HTIP agonist sumatriptan), CCK-I antagonists (e.g. dexloxiglumide), opioid agonists (e.g. asimadoline), N-methyl-D-aspartate (NMDA) receptor antagonists (e.g dextromethorphan), neurokinin antagonists (e.g. talnetant), capsaicin-like agents and antidepressants are among the agents currently under investigation. It seems unlikely, however, that targeting a single mechanism with an individual drug will result in complete symptom remission in most cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据